{"id":3643,"date":"2021-04-13T07:42:00","date_gmt":"2021-04-13T11:42:00","guid":{"rendered":"https:\/\/bridgebioprod.wpengine.com\/?p=3643"},"modified":"2022-06-23T10:14:23","modified_gmt":"2022-06-23T14:14:23","slug":"bridgebio-pharma-inc-and-uc-davis-establish-collaboration-to-transform-research-into-potential-therapies-for-genetically-driven-diseases","status":"publish","type":"post","link":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-inc-and-uc-davis-establish-collaboration-to-transform-research-into-potential-therapies-for-genetically-driven-diseases\/","title":{"rendered":"BridgeBio Pharma, Inc. and UC Davis Establish Collaboration to Transform Research into Potential Therapies for Genetically Driven Diseases"},"content":{"rendered":"\r\n<p>PALO ALTO, Calif. and SACRAMENTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) &#8212; BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with the University of California, Davis (UC Davis), to advance research and the development of investigational medicines for patients with genetically driven conditions and cancers.<\/p>\r\n\r\n\r\n\r\n<p>\u201cUC Davis is a top-tier research university and we feel honored to get the chance to collaborate closely with the talented team there as we work to discover, create, test and deliver breakthrough medicines for people who are suffering from genetic diseases,\u201d said BridgeBio\u00a0founder and CEO Neil Kumar, Ph.D.<\/p>\r\n\r\n\r\n\r\n<p>Under the agreement, the BridgeBio team will work closely with investigators at UC Davis to seek and evaluate potential research projects in genetic disease and precision oncology.<\/p>\r\n\r\n\r\n\r\n<p>\u201cWe have a great appreciation for BridgeBio\u2019s vision to create new pathways that connect innovative research to potential treatments for diseases that may not otherwise be pursued in the marketplace,\u201d said Bill Tucker, interim associate vice chancellor for Innovation and Technology Commercialization at UC Davis. \u201cWe are thrilled to combine our expertise in the hope of expanding the impact of our research to help those in need.\u201d<\/p>\r\n\r\n\r\n\r\n<p>BridgeBio collaborates with stand-out academic institutions, including UC Davis, to support research around genetically driven conditions and is focused on rapidly translating findings into meaningful treatments for patients. Today BridgeBio also announced formal partnerships with Brown University, GlycoNet, The Lundquist Institute, Oregon Health &amp; Science University, Roswell Park Comprehensive Cancer Center and University of California, San Diego \u2013 for a total of 20 partnerships between BridgeBio and leading academic and research institutions to date. For a list of some of the institutions BridgeBio is partnered with, please visit\u00a0<a href=\"http:\/\/bridgebio.com\/partners\" target=\"_blank\" rel=\"noreferrer noopener\">Our Partners<\/a>\u00a0page.<\/p>\r\n\r\n\r\n\r\n<p>With a diverse pipeline encompassing investigational therapies for rare diseases and genetically validated cancers, BridgeBio provides the insights and support needed to rapidly progress therapeutic research from labs to clinical development. BridgeBio intends to develop similar long-term partnerships based on trust, engagement, science and respect to support its mission of developing life-changing medicines for patients with genetically driven conditions as quickly and safely as possible.<\/p>\r\n\r\n\r\n\r\n<p><strong>About BridgeBio Pharma<\/strong><br \/>BridgeBio is a biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio\u2019s pipeline of over 30 development programs ranges from early science to advanced clinical trials and its commercial organization is focused on delivering the company\u2019s first approved therapy. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit\u00a0<a href=\"http:\/\/bridgebio.com\/\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>bridgebiodev.wpengine.com<\/strong><\/a>.<\/p>\r\n\r\n\r\n\r\n<p><strong>BridgeBio Pharma Forward-Looking Statements<\/strong><br \/>This press release contains forward-looking statements. Statements we make in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the \u201cSecurities Act\u201d), and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cExchange Act\u201d), which are usually identified by the use of words such as \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cplans,\u201d \u201cprojects,\u201d \u201cseeks,\u201d \u201cshould,\u201d \u201cwill,\u201d and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements relating to expectations, plans, and prospects regarding our ability to build on the significant advances being made in UC Davis\u2019s labs and translate them into meaningful medicines for patients in need, the success of current and future relationships with third-party collaborators and academic partners, and the potential ability of our product candidates to treat genetically driven diseases and cancers, reflect our current views about our plans, intentions, expectations, strategies and prospects, and are based on the information currently available to us and on assumptions we have made and are neither forecasts, promises nor guarantees. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by these forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, the success of our product candidates to treat genetically driven diseases and cancers, the success of our collaboration with UC Davis, as well as those risks set forth in the Risk Factors section of BridgeBio Pharma\u2019s most recent Annual Report on Form 10-K and BridgeBio Pharma\u2019s other SEC filings. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\r\n\r\n\r\n\r\n<p><strong>BridgeBio Contact:<\/strong><br \/>Grace Rauh<br \/>BridgeBio Pharma, Inc.<br \/><a href=\"mailto:Grace.rauh@bridgebiodev.wpengine.com\" target=\"_blank\" rel=\"noreferrer noopener\">Grace.rauh@bridgebiodev.wpengine.com<\/a><br \/>(917) 232-5478<\/p>\r\n\r\n\r\n\r\n<p><strong>UC Davis Contact:<\/strong><br \/>AJ Cheline<br \/>Director or Marketing and Communications<br \/>UC Davis Office of Research<br \/><a href=\"mailto:acheline@ucdavis.edu\" target=\"_blank\" rel=\"noreferrer noopener\">acheline@ucdavis.edu<\/a><br \/>(530)219-8739<\/p>\r\n","protected":false},"excerpt":{"rendered":"<p>PALO ALTO, Calif. and SACRAMENTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) &#8212; BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with the University of California, Davis (UC Davis), to advance research and the development of investigational medicines for patients with genetically driven conditions and cancers. \u201cUC Davis is a top-tier research university and we [&hellip;]<\/p>\n","protected":false},"author":16,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[10],"tags":[],"class_list":["post-3643","post","type-post","status-publish","format-standard","hentry","category-press-release"],"acf":{"external_link":"","presentation":"","meta_short_title":"BridgeBio and UC Davis Establish Collaboration","meta_description":"BridgeBio Pharma, Inc. and UC Davis Establish Collaboration to Transform Research into Potential Therapies for Genetically Driven Diseases","meta_share_image":false,"people":false},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>BridgeBio and UC Davis Establish Collaboration | BridgeBio<\/title>\n<meta name=\"description\" content=\"BridgeBio announced a collaboration with UC Davis to advance research and the development of medicines for patients with genetically driven conditions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-inc-and-uc-davis-establish-collaboration-to-transform-research-into-potential-therapies-for-genetically-driven-diseases\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BridgeBio and UC Davis Establish Collaboration | BridgeBio\" \/>\n<meta property=\"og:description\" content=\"BridgeBio announced a collaboration with UC Davis to advance research and the development of medicines for patients with genetically driven conditions.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-inc-and-uc-davis-establish-collaboration-to-transform-research-into-potential-therapies-for-genetically-driven-diseases\/\" \/>\n<meta property=\"og:site_name\" content=\"BridgeBio\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-13T11:42:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-06-23T14:14:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Cybele Gouverneur\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@BridgeBioPharma\" \/>\n<meta name=\"twitter:site\" content=\"@BridgeBioPharma\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Cybele Gouverneur\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-inc-and-uc-davis-establish-collaboration-to-transform-research-into-potential-therapies-for-genetically-driven-diseases\/\",\"url\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-inc-and-uc-davis-establish-collaboration-to-transform-research-into-potential-therapies-for-genetically-driven-diseases\/\",\"name\":\"BridgeBio and UC Davis Establish Collaboration | BridgeBio\",\"isPartOf\":{\"@id\":\"https:\/\/bridgebio.com\/#website\"},\"datePublished\":\"2021-04-13T11:42:00+00:00\",\"dateModified\":\"2022-06-23T14:14:23+00:00\",\"author\":{\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/0ccd4f21aad52916b60d0206bb498df7\"},\"description\":\"BridgeBio announced a collaboration with UC Davis to advance research and the development of medicines for patients with genetically driven conditions.\",\"breadcrumb\":{\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-inc-and-uc-davis-establish-collaboration-to-transform-research-into-potential-therapies-for-genetically-driven-diseases\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-inc-and-uc-davis-establish-collaboration-to-transform-research-into-potential-therapies-for-genetically-driven-diseases\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-inc-and-uc-davis-establish-collaboration-to-transform-research-into-potential-therapies-for-genetically-driven-diseases\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bridgebio.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BridgeBio Pharma, Inc. and UC Davis Establish Collaboration to Transform Research into Potential Therapies for Genetically Driven Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/bridgebio.com\/#website\",\"url\":\"https:\/\/bridgebio.com\/\",\"name\":\"BridgeBio\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/bridgebio.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/0ccd4f21aad52916b60d0206bb498df7\",\"name\":\"Cybele Gouverneur\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1310df87abb2898678c7deb92afe7bc4?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1310df87abb2898678c7deb92afe7bc4?s=96&d=mm&r=g\",\"caption\":\"Cybele Gouverneur\"},\"url\":\"https:\/\/bridgebio.com\/author\/cybele-gouverneur\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BridgeBio and UC Davis Establish Collaboration | BridgeBio","description":"BridgeBio announced a collaboration with UC Davis to advance research and the development of medicines for patients with genetically driven conditions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-inc-and-uc-davis-establish-collaboration-to-transform-research-into-potential-therapies-for-genetically-driven-diseases\/","og_locale":"en_US","og_type":"article","og_title":"BridgeBio and UC Davis Establish Collaboration | BridgeBio","og_description":"BridgeBio announced a collaboration with UC Davis to advance research and the development of medicines for patients with genetically driven conditions.","og_url":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-inc-and-uc-davis-establish-collaboration-to-transform-research-into-potential-therapies-for-genetically-driven-diseases\/","og_site_name":"BridgeBio","article_published_time":"2021-04-13T11:42:00+00:00","article_modified_time":"2022-06-23T14:14:23+00:00","og_image":[{"width":1200,"height":600,"url":"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png","type":"image\/png"}],"author":"Cybele Gouverneur","twitter_card":"summary_large_image","twitter_creator":"@BridgeBioPharma","twitter_site":"@BridgeBioPharma","twitter_misc":{"Written by":"Cybele Gouverneur","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-inc-and-uc-davis-establish-collaboration-to-transform-research-into-potential-therapies-for-genetically-driven-diseases\/","url":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-inc-and-uc-davis-establish-collaboration-to-transform-research-into-potential-therapies-for-genetically-driven-diseases\/","name":"BridgeBio and UC Davis Establish Collaboration | BridgeBio","isPartOf":{"@id":"https:\/\/bridgebio.com\/#website"},"datePublished":"2021-04-13T11:42:00+00:00","dateModified":"2022-06-23T14:14:23+00:00","author":{"@id":"https:\/\/bridgebio.com\/#\/schema\/person\/0ccd4f21aad52916b60d0206bb498df7"},"description":"BridgeBio announced a collaboration with UC Davis to advance research and the development of medicines for patients with genetically driven conditions.","breadcrumb":{"@id":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-inc-and-uc-davis-establish-collaboration-to-transform-research-into-potential-therapies-for-genetically-driven-diseases\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bridgebio.com\/news\/bridgebio-pharma-inc-and-uc-davis-establish-collaboration-to-transform-research-into-potential-therapies-for-genetically-driven-diseases\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-inc-and-uc-davis-establish-collaboration-to-transform-research-into-potential-therapies-for-genetically-driven-diseases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bridgebio.com\/"},{"@type":"ListItem","position":2,"name":"BridgeBio Pharma, Inc. and UC Davis Establish Collaboration to Transform Research into Potential Therapies for Genetically Driven Diseases"}]},{"@type":"WebSite","@id":"https:\/\/bridgebio.com\/#website","url":"https:\/\/bridgebio.com\/","name":"BridgeBio","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bridgebio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/bridgebio.com\/#\/schema\/person\/0ccd4f21aad52916b60d0206bb498df7","name":"Cybele Gouverneur","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/bridgebio.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1310df87abb2898678c7deb92afe7bc4?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1310df87abb2898678c7deb92afe7bc4?s=96&d=mm&r=g","caption":"Cybele Gouverneur"},"url":"https:\/\/bridgebio.com\/author\/cybele-gouverneur\/"}]}},"_links":{"self":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts\/3643"}],"collection":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/comments?post=3643"}],"version-history":[{"count":0,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts\/3643\/revisions"}],"wp:attachment":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/media?parent=3643"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/categories?post=3643"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/tags?post=3643"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}